To assess the effect of the addition of three medications to Wegovy on body weight and fat mass, versus Wegovy monotherapy in participants with obesity. Percent body weight change from baseline to week 26, Percent change in total fat mass as measured by DXA from baseline to week 26. There is 17 visits over the 26 week treatment period. Medication is dispensed by subcutaneous injection and IV treatment. Compensation for time and travel is up to $1951.00.
- Ages 18-80
- BMI of greater than 30
- History of one or more unsuccessful weight loss attempts
- THIS TRIAL IS NOT FOR DIABETICS